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Abstract 
Background: In Henan, China, first-line antiretroviral treatment (ART) was implemented early in a large number 
of treatment-experienced patients who were more likely to have a drug resistance. Therefore, we investigated the 
human immunodeficiency virus (HIV)-1 drug resistance profiles among patients in Henan who experienced virologi-
cal failure to ART.
Method: A cross-sectional survey was administered in 10 major epidemic cities from May 2010 to October 2011. 
Adult patients who experienced virological failure (virus load ≥1,000 copies/mL) with >1 year of first-line antiretrovi-
ral treatment consented to provide blood for genotype resistance testing. The clinical and demographic data were 
obtained from the patients’ medical records. Logistic regression analysis was performed to determine the factors 
associated with ≥1 significant drug resistance mutation.
Results: We included 3,235 patients with integral information and valid genotypic resistance data. The city, age, CD4 
counts, virus load, treatment duration, and World Health Organization stage were associated with drug resistance, 
and 64.76% of patients acquired drug resistance. The nucleoside reverse transcriptase inhibitor (NRTI), non-(N)NRTI, 
and protease inhibitor resistance mutations were found in 50.26, 63.12, and 1.30% of subjects, respectively. Thymidine 
analogue mutations, NNRTI and even multidrug resistance complex were quite common in this patient cohort.
Conclusion: Multiple and complex patterns of HIV-1 drug resistance mutations were identified among individuals 
who experienced virological failure to first-line ART in Henan, China during 2010–2011. Therefore, timely virological 
monitoring, therapy adjustments, and more varieties of drugs and individualized treatment should be immediately 
considered in this patient population.
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Background
Continuous improved antiretroviral therapy (ART) has 
been one of the most significant breakthroughs in human 
immunodeficiency virus (HIV)/acquired immune defi-
ciency syndrome (AIDS) prevention and control over the 
past 30 years because of its outstanding effect on reduc-
ing AIDS mortality and morbidity [1, 2], ameliorating 
quality of life, and preventing HIV-1 infection [3]. How-
ever, the emergence of HIV drug resistance is inevitable 
following the large-scale rollout of ART. The enhanced 
resistance to first-line antiretroviral drugs has led to 
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persistent viral replication that impairs patients’ immu-
nological and clinical status, and the accumulation of 
resistance mutations after continuing a failing regimen 
may compromise the second-line therapy [4]. To maxi-
mize the long-term effectiveness of first-line ART regi-
mens and to ensure the sustainability of ART programs, 
it is essential to minimize the further spread of HIV drug 
resistance. The World Health Organization (WHO) rec-
ommends that the scale-up of HIV ART should always be 
accompanied by a robust assessment of drug resistance 
emergence [5].
The Chinese government initiated the China Compre-
hensive AIDS Response program to provide free HIV 
treatment in 2002, which rapidly scaled up the National 
Free Antiretroviral Therapy Program. Subsequently, drug 
resistance surveillance in different areas was attempted, 
and the popularization of drug resistance monitoring 
was performed in 2010. The Henan Province has always 
drawn concern because of the extensive spread of HIV 
among former plasma donors and the earlier initiation 
of the National Free ART Program with a large num-
ber of ART patients [6, 7]. Numerous HIV drug resist-
ance studies with heterogeneous designs, defined areas, 
and methods have been performed in China with small 
populations from Henan [8–11]; however, until recently, 
few studies have illuminated the typical prevalence and 
pattern of HIV drug resistance in the Henan Province. 
Therefore, we assessed the HIV-1 drug resistance profile 




The administration of ART, delivery of antiviral drugs, 
adherence education, and collection of plasma speci-
mens mainly depended on the local centers for disease 
control and prevention (CDC) and the community clin-
ics in the Henan Province. The CD4 cell counts were 
measured twice and virus load were measured once 
1 year by a local CDC and Henan CDC, and the results 
were provided to treating physicians and the national 
HIV/AIDS case reporting system. All the cases of HIV/
AIDS in China are reported via the national HIV/AIDS 
case reporting system. Records in this system include 
identity and demographic information, HIV testing 
results, the self-reported transmission route, and health 
status information. Base data for this study was derived 
from this system. For the purpose of this study, viro-
logical failure patients (defined as having an HIV virus 
load of ≥1,000 copies/mL) underwent genotypic drug 
resistance testing and the results were also provided 
to treating physicians and the national HIV/AIDS case 
reporting system.
Ethics statement
Written consent was obtained from patients to partici-
pate in the China’s routine HIV/AIDS surveillance pro-
gram and the regular administration of the national ART 
program, and parental consent was also obtained on 
behalf of the participants aged less than 18  years. Since 
the data and the samples used in this study were collected 
as a function of surveillance program above, no addi-
tional informed consent was required. This study was 
reviewed and approved by the Institutional Review Board 
of the Henan CDC.
Participants
According to the aforementioned conditions, first-line 
ART-virological failure patients (aged ≥15  years) were 
selected if the virus load was ≥1,000 copies/mL with 
>1  year of treatment from May 2010 to October 2011 
in 10 cities that held the highest HIV-1 epidemic in the 
Henan Province. The patients could not followed or 
refused to give samples were not included. The first-line 
ART regimens consisted of two nucleoside reverse tran-
scriptase inhibitors (NRTIs): (azidothymidine [AZT] or 
stavudine [D4T])  +  (didanosine [DDI] or lamivudine 
[3TC]) and one non-(N)NRTIs: (nevirapine [NVP] or efa-
virenz [EFV]). AZT, D4T, DDI, and NVP are generically 
produced in China, whereas 3TC and EFV are branded 
drugs that became available in 2005.
Laboratory tests
The CD4 cell counts were measured using flow cytom-
etry by the local CDCs. The plasma HIV-1 virus load 
was tested by the local city and Henan CDCs using the 
Abbott Real-Time HIV-1 assay (Abbott Molecular Inc., 
Des Plaines, IL, USA), NucliSENS EasyQ-EasyMag HIV-1 
assay (bioMerieux, Marcy l’Etoile, France), or Cobas 
AmpliPrep-Cobas TaqMan HIV-1 assay (Roche Diag-
nostics, Mannheim, Germany). Samples with a virus load 
of ≥1,000 copies/mL underwent HIV-1 drug resistance 
genotyping using an in-house method developed by the 
national core laboratories as described in previous stud-
ies [12, 13]. A fragment of the HIV-1 pol gene (protease, 
amino acids 1–99, and part of the reverse transcriptase 
amino acids 1–252) was bulk-sequenced from the plasma 
ribonucleic acid (RNA). The resulting fragment was ana-
lyzed for subtype, drug resistance mutations and drug 
susceptibility using the Stanford HIV Drug Resistance 
Database (http://hivdb.stanford.edu).
Data analysis
The demographic variables were analyzed using descrip-
tive statistics, and the risk factors for developing HIV 
drug resistance were analyzed using logistic regression. 
Variables associated with resistance in the univariate 
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analyses (p value <0.05) and those clinically meaningful 
were included in the multivariable regression model. The 
tests were two-sided, and a p-value <0.05 indicated sta-
tistical significance. All the statistical analyses were per-




In our study, 4,020 individuals were investigated and sam-
pled, which included 23 non-Henan, 154 dual-tested. 
Moreover, 81 patients with incomplete information and 
527 with a fragmentary sequence were excluded, leav-
ing 3,235 subjects in the final analysis (Table 1). The fol-
lowing five cities accounted for a substantially larger 
proportion: Zhumadian (22.97%), Kaifeng (19.07%), 
Shangqiu (18.89%), Zhoukou (17.25%), and Nanyang 
(11.16%) (Figure  1). Of the 3,235 patients, 63.37% were 
aged 31–50  years, 52.49% were male, 82.87% were mar-
ried, 90.11% reported former plasma donors as the route 
of HIV infection, 39.54% had WHO stage II HIV dis-
ease, 51.56% had been treated for >6 years, 27.02% have 
CD4 counts ≥350 cells/μL, 58.83% have virus load in 
between 3 and 4 log copies/ml. All the 3235 individu-
als were B subtypes. ART was initialized with AZT/
D4T + DDI + NVP/EFV in 1,428 subjects (44.14%), with 
AZT/D4T + 3TC + NVP/EFV in 1,170 (36.17%). The reg-
imen that included DDI was substituted with a regimen 
that included 3TC after 2005 when it was widely available.
Risk factors associated with genotypic human 
immunodeficiency virus drug resistance
Exploratory logistic regression analysis was performed to 
assess the factors that were significantly associated with 
resistance (Table 1). According to the univariate logistic 
regression model, eight potential factors correlated with 
HIV drug resistance. In the multivariate model, the fol-
lowing six factors had correlations: the city (patients 
in Xinyang had the highest level of drug resistances, 
79.27%); age (patients in <30 years group had the highest 
level of drug resistance, 78.65%); CD4 counts (patients in 
<50 cells/μL group had the highest level of drug resist-
ance, 71.01%); Virus load (patients in 3-4 log copies/ml 
group had the highest level of drug resistance, 67.47%); 
WHO stage (patients in WHO stage III group had the 
highest level of drug resistance, 66.63%); and treatment 
duration (patients in 5–6  years group had the highest 
level of drug resistance, 72.81%).
Pattern and frequency of predicted HIV drug resistance 
mutations
At least one significant HIV drug resistance mutation 
was identified in 2,095 (64.76%) patients, according to the 
Stanford HIV Drug Resistance Database. The frequency 
of NNRTI, NRTI, and PI resistance mutations were 63.12, 
50.26, and 1.30%, respectively. In this study, 42.60% of 
patients had both NRTI and NNRTI resistance muta-
tions, 7.67% had NRTI but not NNRTI, and 20.53% had 
NNRTI but not NRTI resistance mutations (Figure 2).
M184  V/I (35.64%) emerged as the most common 
NRTI resistance mutation, followed by thymidine ana-
logue mutations (TAMs): T215Y/F (27.17%), M41L 
(18.39%), D67  N (12.21%), K70R/E/G (10.20%), L210  W 
(10.17%), and K219E/Q (10.02%). The prevalence of 
>1 TAMs was 42.32%. Furthermore, the prevalence 
of M184  V/I  +  TAMs was 21.36%, TAMs-1 (M41L, 
L210  W, and T215Y) was 8.96%, and TAMs-2 (D67  N, 
K70R, T215F, and K219Q) was 4.61%. Fifty-one (1.58%) 
and thirteen (0.40%) patients had the K65R/N and 
Q151 M complex, respectively. Among the NNRTI resist-
ance mutations, K103 N (34.84%) was the most common 
NNRTI, followed by Y181C/V/I (22.04%) and G190A/S/E 
(18.24%) (Table 2).
Estimated susceptibility to various antiretroviral drugs
Mutational patterns were used to estimate the drug sus-
ceptibility in patients based on the Stanford University 
HIV Drug Resistance Database (Figure  3). Of the 40.93 
and 40.90% subjects in this cohort had an estimated 
resistance against 3TC and FTC; 35–37% against ABC, 
AZT, D4T, and DDI; and 26.89% against TDF. There was 
a comparatively high prevalence of an estimated resist-
ance to EFV and NVP, which reached 62–63%, and 0.62% 
of the subjects had a resistance to lopinavir.
Discussion
ART has expanded in Henan during the last decade, and 
the continued success of ART programs will require an 
understanding of the profiles of HIV drug resistance 
among individuals in whom the treatment has failed. This 
study’s findings demonstrated the presence of HIV drug 
resistance among individuals from the Henan Province 
of China (2010–2011) in whom the first-line therapy had 
virologically failed.
In the early years, the magnitude of the focus was on 
former plasma donors, however, with the change of the 
HIV epidemic, sexual intercourse has been the focus of 
HIV/AIDS control and prevention, which has attracted 
substantial resources [14–17]. This study had a large 
number of subjects, and 90.11% of the virological failure 
population accounted for former plasma donors. This 
finding indicates that these people also currently occupy 
an important position in the ART programs; thus, meas-
urements such as virology surveillance, drug resistance 
monitoring, therapy adjustments, and related social secu-
rity need to be ensured.
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Table 1 The subjects’ characteristic and  the factors associated with  at least one human immunodeficiency virus (HIV) 
drug resistance mutation
Variable Number (%) HIV drug resistance (%) Crude OR (95% CI) P-value Adjusted OR (95% CI) P-value
City
 Zhumadian 743 (22.97) 481 (64.74)
 Zhengzhou 81 (2.50) 38 (46.91) 0.5 (0.3,0.8) 0.00 0.8 (0.5,1.4) 0.49
 Kaifeng 617 (19.07) 329 (53.32) 0.6 (0.5,0.8) 0.00 0.7 (0.6,0.9) 0.01
 Jiaozuo 48 (1.48) 26 (54.17) 0.6 (0.4,1.2) 0.14 0.8 (0.4,1.6) 0.59
 Zhoukou 558 (17.25) 352 (63.08) 0.9 (0.7,1.2) 0.54 1.1 (0.9,1.5) 0.33
 Pingdingshan 13 (0.40) 11 (83.33) 3.0 (0.7,13.6) 0.16 3.1 (0.7,14.8) 0.15
 Luohe 121 (3.74) 85 (70.25) 1.3 (0.8,2.0) 0.24 1.7 (1.1,2.8) 0.02
 Shangqiu 611 (18.89) 440 (72.01) 1.4 (1.1,1.8) 0.00 1.5 (1.2,1.9) 0.00
 Nanyang 361 (11.16) 268 (74.24) 1.6 (1.2,2.1) 0.00 1.9 (1.4,2.5) 0.00
 Xinyang 82 (2.53) 65 (79.27) 2.1 (1.2,3.6) 0.01 2.4 (1.3,4.4) 0.00
Age
 ≤30 89 (2.75) 70 (78.65)
 31–50 2,050 (63.37) 1,295 (63.17) 0.5 (0.3,0.8) 0.00 0.5 (0.2,0.8) 0.01
 >50 1,096 (33.88) 730 (66.61) 0.5 (0.3,0.9) 0.02 0.5 (0.3,0.9) 0.03
Gender
 Female 1,537 (47.51) 1,011 (65.78)
 Male 1,698 (52.49) 1,084 (63.84) 0.9 (0.8,1.1) 0.25
Married
 No 2,681 (82.87) 1,737 (64.79)
 Yes 554 (17.13) 358 (64.62) 1.0 (0.8,1.2) 0.94
HIV transmission route
 FPD 2,915 (90.11) 1,909 (65.49)
 Sexual intercourse 238 (7.36) 139 (58.40) 0.7 (0.6,1.0) 0.03 1.1 (0.8,1.5) 0.71
 Mother-to-Child 24 (0.74) 22 (91.67) 5.8 (1.4,24.7) 0.02 3.3 (0.7,16.6) 0.14
 Other 58 (1.79) 25 (43.10) 0.4 (0.2,0.7) 0.00 0.8 (0.4,1.4) 0.36
CD4
 ≥350 874 (27.02) 536 (61.33)
 200–349 1,112 (34.37) 718 (64.57) 0.9 (0.7,1.1) 0.20 0.9 (0.7,1.2) 0.52
 50–199 1,011 (31.25) 672 (66.47) 1.3 (1.0,1.7) 0.03 1.4 (1.1,1.9) 0.01
 <50 238 (7.36) 169 (71.01) 1.9 (1.3,2.7) 0.00 2.6 (1.7,4.0) 0.00
Virus load
 >4log 1,332 (41.47) 811 (60.89)
 3–4log 1,903 (58.83) 1,284 (67.47) 1.4 (1.1,1.9) 0.01 1.6 (1.1,2.0) 0.01
Initial ART regimen
 AZT/D4T + DDI + EFV/NVP 1,428 (44.14) 975 (68.28)
 AZT/D4T + 3TC + EFV/NVP 1,170 (36.17) 714 (61.03) 0.7 (0.6,0.9) 0.00 1.0 (0.8,1.2) 0.85
 Other regimens 637 (19.69) 406 (63.74) 0.8 (0.7,1.0) 0.04 0.9 (0.8,1.2) 0.61
WHO stage
 I 635 (19.63) 382 (60.16)
 II 1,279 (39.54) 829 (64.82) 1.2 (1.0,1.5) 0.05 1.1 (0.9,1.4) 0.32
 III 860 (26.58) 573 (66.63) 1.3 (1.1,1.6) 0.01 1.4 (1.0,1.7) 0.01
 IV 226 (6.99) 146 (64.60) 1.2 (0.9,1.7) 0.24 1.4 (1.0,1.9) 0.08
 No information 235 (7.26) 165 (70.21) 1.6 (1.1,2.2) 0.01 0.9 (0.6,1.3) 0.63
Duration of ART (year)
 7– 930 (28.75) 650 (70.49)
 6– 738 (22.81) 502 (68.02) 0.9 (0.7,1.1) 0.41 0.9 (0.7,1.1) 0.24
 5– 331 (10.23) 241 (72.81) 1.2 (0.9,1.5) 0.32 0.9 (0.7,1.2) 0.60
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The prevalence of HIV drug resistance is not constant 
across Henan. Zhumadian, Kaifeng, Shangqiu, Nanyang, 
and Xinyang have assembled a great deal of resources in 
the field of HIV/AIDS control and prevention because of 
their high HIV epidemic [14]. Compared to Zhumadian, 
multivariate analysis showed that Shangqiu, Nanyang, 
and Xinyang were associated with a higher likelihood 
of drug resistance mutations, whereas Kaifeng was not. 
Similarly, the other five cities also have the disconcord-
ance phenomenon. These findings clarified that the scale 
of epidemic and resource focus on HIV/AIDS control 
and prevention has no direct correlation with the devel-
opment of HIV drug resistance; however like other study 
had set forth, the local ART programmatic factors play a 
significant role [10]. Patients with low CD4 counts (below 
200 cells/μL) and long-time treatment(over 4-years) were 
at the high risk of HIV drug resistance in this study that 
can be easily understood. The lower virus load(3–4 log 
copies/ml other than >4 log copies/ml) were correlated 
Table 1 continued
Variable Number (%) HIV drug resistance (%) Crude OR (95% CI) P-value Adjusted OR (95% CI) P-value
 4– 264 (8.16) 182 (68.94) 1.0 (0.7,1.3) 0.77 0.7 (0.5,1.0) 0.05
 3– 253 (7.82) 171 (67.59) 0.9 (0.7,1.2) 0.48 0.6 (0.4,0.9) 0.00
 2– 289 (8.93) 183 (63.32) 0.7 (0.6,1.0) 0.04 0.5 (0.4,0.7) 0.00
 1– 430 (13.29) 166 (38.60) 0.3 (0.2,0.3) 0.00 0.2 (0.1,0.2) 0.00
Figure 1 The geographical distribution of subjects according to the cities analyzed in this study. a The geographical distribution of treatment fail-
ures. b The geographical distribution of drug resistance genotypes detected. The abbreviation of city names are ZMD (Zhumadian), ZZ(Zhengzhou), 
KF(Kaifeng), JZ(Jiaozuo), ZK(Zhoukou), PDS(Pingdingshan), LH(Luohe), SQ(Shangqiu), NY(Nanyang), XY(Xinyang). The number and percentage in the 
brackets are the absolute number of subjects and the percent in the 3235 individuals. Heavy gray, cities with >10% of subjects; light gray, cities with 
<10% of subjects.
Figure 2 The prevalence of predicted human immunodeficiency 
virus 1 drug resistance mutations in different drug classes among 
individuals experiencing virological failure to first-line antiretroviral 
treatment in Henan, China during 2010–2011. N+NN+ the existence 
of both nucleoside reverse transcriptase inhibitor (NRTI) and non-(N)
NRTI resistance mutation, N+NN− the existence of NRTI but not 
NNRTI resistance mutations, N-NN+ the existence of NNRTI but not 
NRTI resistance mutations.
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to the high risk of HIV drug resistance mainly because of 
the HIV drug resistance strains were defective virus, and 
it probably have a lower capability of replication [4, 18].
NNRTIs have a low genetic barrier to resistance. There-
fore, a single mutation is often sufficient for causing 
resistance to the currently recommended first generation 
of NNRTIs, NVP, or EFV [19, 20], which is why the sec-
ond-line therapy did not include NNRTIs. Henan ini-
tiated the switch to second-line ART in patients who 
experienced failure with the first-line treatment in 2009. 
In this study, the prevalence of NNRTI resistance muta-
tions (63.12%) was approximately equal to the total 
resistance mutations (64.76%). In addition, 20.53% of 
the patients had the NNRTI resistance mutations with-
out NRTI, while only 7.67% had NRTI without NNRTI. 
Lastly, the prevalence of estimated resistance against 
EFV (62.87%) and NVP (63.00%) was both high with no 
significant different. All of these findings illustrated that 
the NNRTI resistance was more pervading than NRTI in 
ART failure patients. Therefore, it is just and reasonable 
for the government to perform second-line ART.
As expected, M184  V/I was the most commonly 
detected NRTI resistance mutation, which was also 
found in previous studies [21, 22], and this was followed 
by a high frequency of TAMs. A comparative amount of 
TAMs-1 and TAMs-2 were also detected in this study. 
TAMs confer cross-resistance to AZT and D4T as well 
as to most NRTIs in varying degrees when enough 
TAMs have accumulated. Additionally, two typical 
TAM pathways with a high resistance to all NRTIs were 
discovered: TAM-1 (M41L, L210W, and T215Y) and 
TAM-2 (D67N, K70R, K219E/Q, and T215F) [23–25]. 
Fewer K65R and Q151M complexes were detected in 
the study, mainly because they were apt to other sub-
types and regimens [26, 27]. The Q151M complexes 
and K65R were also resistance mutations to multiple 
or even all of the NRTIs. The Q151M complex con-
fers resistance to all NRTIs, except for TDF [28], and 
K65R confers resistance to D4T and TDF and possibly 
also to 3TC/FTC, DDI, and ABC [29]. Among patients 
with a detectable HIV RNA at 12 months, the HIV drug 
resistance was primarily due to M184V and NNRTI 
Table 2 Frequency of  the predicted human immunodefi-
ciency virus drug resistance mutations
Resistance mutation (n = 3,235) No. of patients (%)
NRTI mutation
 M184V/I 1,153 (35.64)
 T215Y/F 879 (27.17)
 M41L 595 (18.39)
 D67N 395 (12.21)
 K70R/E/G 330 (10.20)
 L210 W 329 (10.17)
 K219E/Q 324 (10.02)
 L74I/V 118 (3.65)
 V75I/M 110 (3.40)
 Q151 M 93 (2.87)
 A62 V 74 (2.29)
 F116Y 67 (2.07)
 K65R/N 51 (1.58)
 F77L 30 (0.93)
 Y115F 9 (0.28)
 ≥1TAM 1,369 (42.32)
 TAM-1 290 (8.96)
 TAM-2 149 (4.61)
 TAM-1/TAM-2 10 (0.31)
 Q151 M complex 13 (0.40)
 M184 V/I + TAMs 691 (21.36)
NNRTI mutation
 K103 N/S 1,127 (34.84)
 Y181C/V/I 713 (22.04)
 G190A/S/E 590 (18.24)
 K101E/P 247 (7.64)
 V108I 225 (6.96)
 V106A/M 177 (5.47)
 Y188L/C/H 140 (4.33)
 F227L/C 121 (3.74)
 K238T 117 (3.62)
 V179D/E/F 93 (2.87)
 P225H 63 (1.95)
 A98G 53 (1.64)
 L100I 11 (0.34)
 P236L 1 (0.03)
PI mutation
 M46I/L 22 (0.68)
 V82F 11 (0.34)
Figure 3 Prevalence of the genotypic resistance against different 
antiretroviral treatment (ART) drugs among individuals experiencing 
virological failure to first-line ART in Henan, China during 2010–2011.
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mutations. Complex mutation patterns, including the 
TAMs, K65R, and multinucleoside mutations, are prev-
alent among cases of treatment failure that were identi-
fied by clinical or immunologic methods as a result of 
the accumulation of drug resistance [21, 22]. The accu-
mulation of drug resistance depends on the frequency of 
monitoring [30] and belated regimen adjustment. Thus, 
the duration of virologic failure must be somewhat 
longer than it should be because of the delayed virol-
ogy surveillance or therapy adjustment in Henan dur-
ing 2010–2011. Meanwhile, as Figure 3 shows, 35–40% 
of patients showed an estimated resistance against most 
NRTIs with 40.39 and 26.89% against 3TC and TDF, 
respectively. Since the second-line ART consists of two 
NRTIs (usually 3TC and TDF) and one PI, all of these 
findings suggest that a considerable amount of patients 
in Henan may already be compromised to second-line 
ART, indicating that approaches to more newer drugs 
with different mechanisms and individualized treatment 
should be considered sooner.
The emergence of transmitted HIV drug resistance 
can be anticipated, because such a large quantity of indi-
viduals acquired HIV drug resistance in this population-
based survey. Recently, a moderate level of prevalence for 
transmitted HIV drug resistance has been reported in 
Henan [31]. More active monitoring strategies, such as 
conducting drug resistance testing prior to the initiation 
of ART should be performed as recommended by WHO 
in developed countries [32, 33].
Drug resistance mutations were undetected in 35.26% 
of patients among this treatment failure cohort, a sig-
nificant proportion of individuals without mutations for 
treatment failure has also been reported in all similarity 
studies [5]. This probably because HIV drug resistance 
presented in some patients as minority variants (lower 
than 10–20% of the virus population) that may pass 
undetected by Sanger sequencing method [18], and non-
adherence or treatment interruption must be another eti-
ology of treatment failure without drug resistance. This 
study has gaps in knowledge on adherence, and we were 
not able to determine the duration of virological failure 
by using a cross-sectional survey. In view of these limita-
tions, a further study needs to be conducted to provide 
sufficient evidence for evaluating a more precise and 
comprehensive profile of drug resistance among ART 
failures in Henan.
Conclusion
In conclusion, long-term ART roll-out leads to a com-
paratively high prevalence of HIV drug resistance among 
individuals who have experienced virological failure to 
first-line ART in Henan during 2010–2011, indicating a 
magnitude of former plasma donors. Multiple mutations 
and complex patterns have been identified, which may 
cause a growing number of those being treated with sec-
ond-line therapy with partial or no activity. Performing 
routine drug resistance surveillance programs and timely 
therapy adjustment, especially among former plasma 
donors, ensuring access to new kinds of drugs, and initi-
ating individualized treatment must be a priority in order 
to preserve programmatic treatment success in long-life 
therapy.
Data and materials availability Sequences generated 
for this study were deposited in the national AIDS treat-
ment database of China.
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